98300-35-7

Upstream product

• 126522-15-4 2-azido-3,6-dimethoxyacetophenone 
• 113396-53-5 2-acetyl-3-azidohydroquinone 
• 1125-55-9 2-Acetyl-1,4-benzoquinone 
• 1201-38-3 2',5'-dimethoxyacetophenone 
• 90923-05-0 2,5-dimethoxy-6-nitroacetophenone 

Downstream Products

• 98300-36-8 2'-(N-2-carbethoxyethylamino)-3',6'-dimethoxyacetophenone 
• 234752-09-1 2-amino-5-bromo-3,6-dimethoxyacetophenone 
• 108711-19-9 (2-Acetyl-3,6-dimethoxy-phenyl)-carbamic acid ethyl ester 

Relevant academic research and scientific papers

Concise synthesis of tetrahydro derivatives of the pyrido[2,3-b]acridine and pyrido[3,2-b]acridine ring systems

5,6,7,8-Tetrahydro-1,4-acridinequinones were readily prepared by Friedlander reaction between cyclohexanone and 2-amino-3,6- dimethoxybenzaldehydes or 2-amino-3,6-dimethoxyacetophenones, followed by oxidative demethylation. Their Diels-Alder reactions wit

Synthesis of 1,2,3,4-tetrahydroascididemin

1,2,3,4-Tetrahydroascididemin was synthesized in six steps from 2- nitro-3,6-dimethoxyacetophenone. The core linear tetracyclic pyrido[2,3- b]acridine system (6) was prepared through combination of a Friedlander reaction and an hetero Diels-Alder cycloadd

STUDIES ON THE SYNTHESIS OF FUSED HETEROCYCLES FROM o-AMINOCARBONYL COMPOUNDS

Convenient preparations of 6-amino-2,5-dimethoxyacetophenone and benzaldehyde (3,6), and heterocyclization of these to produce benzisoxazol, quinoline amd cinnolinesystems are described.

Synthesis and Cardiotonic Activity of a Series of Substituted 4-Alkyl-2(1H)-quinazolinones

The synthesis, cardiac fraction III cyclic nucleotide phosphodiesterase (PDE-III) inhibition, and positive inotropic activity of a series of 2(1H)-quinazolinones are reported.A general synthesis of the series involved the cyclization of 2-aminoacetophenones with potassium cyanate in acetic acid.Modifications at the 4-position of the quinazoline nucleus were best achieved by formation of the intermediate N1-acyl-N3-phenylurea from the substituted phenyl isocyanate and appropriate carboxamide.PPA was used to ring close to the quinazoline product.Generally the SAR for the series paralleled the five-point model previously published for PDE-III inhibition.The most active analogue of the series was 5,6-dimethoxy-4-methyl-2(1H)-quinazolinone (1) (ORF 16600), which had about twice the intravenous potency of amrinone.Compound 1 is currently under development as an orally active cardiotonic.